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Essentials
• Inflammation plays a key role in the development of colorectal cancer.
• Understanding mechanisms of cancer initiation might reveal new anticancer preventive strategy.
• Hyperactive platelets promote tumor formation by fostering immune evasion of cancer.
• Platelet inhibition by clopidogrel prevents carcinogenesis by restoring antitumor immunity.
Summary. Background: Clinical and experimental evidence support a role for inflammation in the development of colorectal cancer, although the mechanisms are not fully understood. Beyond thrombosis and hemostasis, platelets are key actors in inflammation; they have also been shown to be involved in cancer. However, whether platelets participate in the link between inflammation and cancer is unknown. Objective: To investigate the contribution of platelets and platelet-derived proteins to inflammation-elicited colorectal tumor development. Methods: We used a clinically relevant mouse model of colitis-associated cancer. Platelet secretion and platelet reactivity to thrombin were assessed at each stage of carcinogenesis. We conducted an unbiased proteomic analysis of releasates of platelets isolated at the pretumoral stage to identify soluble factors that might act on tumor development. Plasma levels of the identified proteins were measured during the course of carcinogenesis. We then treated the mice with clopidogrel to efficiently inhibit platelet release reaction. Results: At the pretumoral stage, hyperactive platelets constituted a major source of circulating protumoral serum amyloid A (SAA) proteins. Clopidogrel prevented the early elevation of the plasma SAA protein level, decreased colitis severity, and delayed the formation of dysplastic lesions and adenocarcinoma. Platelet inhibition hindered the expansion and function of immunosuppressive myeloid cells, as well as their infiltration into tumors, but increased the number of tissue CD8 + T cells. Platelets and releasates of platelets from mice with cancer were both able to polarize myeloid cells towards an immunosuppressive phenotype. Conclusions: Thus, platelets promote the initiation of colitis-associated cancer by enhancing myeloid cell-dependent immunosup
Introduction
Colorectal cancer (CRC) is the fourth most common cancer worldwide, and the third leading cause of cancerrelated death in women and men [1] . Inflammatory bowel disease is an important risk factor for the development of Correspondence: C ecile Oury, University of Li ege, GIGA-Cardiovascular Sciences Laboratory of Thrombosis and Hemostasis and Valvular Heart Disease, GIGA B34, Avenue de l'Hôpital, 1, B-4000 Li ege, Belgium Tel.: +32 4 366 2487 E-mail: cecile.oury@ulg.ac.be CRC. Inflammation is also likely to be involved in other forms of CRC [2] , although the mechanisms remain largely unknown.
Mouse models of colitis-associated cancer (CAC) have shown that recruitment of immune cells to the inflamed intestinal tissue contributes to carcinogenesis [3, 4] . Immunosuppressive cells of myeloid origin are essential to promote mouse colitis-associated tumorigenesis through inhibition of CD8 + T-cell cytotoxic activity [5, 6] . These cells, referred to as granulocytic myeloid-derived suppressor cells (G-MDSCs) and monocytic myeloidderived suppressor cells (M-MDSCs), accumulate in pathological conditions such as cancer and inflammatory diseases [7] [8] [9] [10] . Immunosuppressive G-MDSCs are found in the blood of tumor-bearing mice and cancer patients. They exist within a heterogeneous population of low-density neutrophils (LDNs) that show altered functions as compared with normal-density neutrophils (NDNs) [11] . However, the mechanisms responsible for the expansion and polarization of these immunosuppressive cells are not fully understood [12] [13] [14] .
In addition to their central role in thrombosis and hemostasis, platelets contribute to inflammation via their ability to secrete proinflammatory cytokines and chemokines, and through functional interactions with leukocytes and non-immune cells (e.g. endothelial cells) [15] [16] [17] [18] . Moreover, activated platelets can promote the production of the anti-inflammatory interleukin (IL)-10 and inhibit tumor necrosis factor-a secretion by monocytes/macrophages, thereby limiting the inflammatory response [19] . They have also been implicated in cancer development [20] , and the dissemination of metastasis [21] . Activated platelets release growth factors, including vascular endothelial growth factor, transforming growth factor (TGF)-b1, insulin-like growth factor I, and platelet-derived growth factor, from their a-granules, acting on angiogenesis and tumor growth. Platelet-derived microparticles can also have proinflammatory or immunosuppressive effects, and contribute to both angiogenesis and metastasis [22] . Platelets promote the recruitment of bone marrow-derived cells, which stimulates tumorigenesis [23] . However, whether platelets can regulate the function of immunosuppressive myeloid cells has never been investigated.
Cancer itself has an impact on platelets [24] . Tumor cells induce the generation of thrombin, a strong platelet agonist [25] . Cancer causes the recruitment of newly activated circulating platelets that are hyper-reactive, and platelet aggregates are found within the tumor vasculature. Thrombocytosis is associated with a poor prognosis in colon, breast, lung, gastric, renal, cervical, pancreatic, endometrial, brain and ovarian cancers [26, 27] .
In our study, we used the clinically relevant azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse model of CAC [28, 29] to investigate whether platelets regulate inflammation-dependent cancer development. This mouse model has been proven to rapidly recapitulate the aberrant crypt foci (dysplasia)-adenoma-carcinoma sequence that occurs in human CRC. We used a protocol that mimics chronic inflammation, which is believed to be the driving force in the carcinogenesis of colitis-associated CRC, as seen in inflammatory bowel diseases. We performed a proteomic analysis, and identified serum amyloid A (SAA) proteins in releasates of platelets from early-stage cancer mice. We show that inhibition of platelet release with clopidogrel mitigates carcinogenesis by altering myeloid cell immunosuppressive expansion and function. We demonstrate that platelets contribute to myeloid cell polarization to a suppressive phenotype.
Materials and methods
Detailed methods are provided as Supporting information in methods section.
Ethical statements
This study was carried out in strict accordance with the guidelines for the care and use of animals in the European Union. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Li ege (permit 1348).
AOM/DSS model and disease activity index (DAI) score
Male C57Bl/6J mice (aged 5 weeks) were obtained from Charles River Laboratories (Chatillon-sur-Chalaronne, France). The AOM/DSS model was applied as described previously [28, 30] (Fig. 1A) . AOM was injected intraperitoneally (12 mg kg
À1
) on the first day of the protocol, according to established methods [31] . Chronic inflammation was induced by three cycles of 2% DSS administered via the drinking water [32] . Some mice were continuously treated with 30 mg kg À1 clopidogrel orally. We verified that this treatment fully inhibited the ex vivo aggregation of washed mouse platelets induced by ADP (50 lM) or by thrombin (0.1 U mL À1 ) (Fig. S1A,C) . Clopidogrel also inhibited ADP-induced CD62P membrane expression and a IIb b 3 integrin expression, as assessed by flow cytometry (Fig. S1B ). The DAI score was calculated by scoring weight loss, stool consistency and bleeding as described by Guo et al. [33] .
Histopathological analysis and immunohistochemistry
Tumor grade was determined on hematoxylin and eosinstained colon sections in a blinded manner, based on the revised Vienna classification of gastrointestinal epithelial neoplasia [34] . Images were captured with an FSX-100 Microscope (Olympus, Berchem, Belgium). Immunohistochemical analyses of colon sections were performed with the indicated antibodies. For quantification, 9 20 scanned images were used. A minimum of eight fields of tumoral or non-adenomatous mucosa on three sections per mouse group were analysed. The number of stained cells was counted by use of the colour deconvolution plugin in IMAGEJ.
Flow cytometry
Flow cytometry analyses of myeloid cell populations were performed in mouse EDTA-anticoagulated whole blood samples (FACS Verse; BD Biosciences, Erembodegem, Belgium). Absolute cell counts were determined on the basis of total white blood cell counts measured in the same blood samples (Cell Dyn-3700 System; Abbott, Rungis, France). Flow cytometry analyses of platelet activation and platelet-myeloid cell aggregates were performed in citrate-anticoagulated whole blood samples, as previously described [35] . Analyses of flow cytometry data were performed with BD FACSUITE software.
Washed platelet preparation
Mouse washed platelets were prepared from peripheral blood collected from the retro-orbital plexus in acid-citrate-dextrose containing 1 U mL À1 apyrase (SigmaAldrich, Overijse, Belgium), as previously described [36] . ) (means values AE SEM, *P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wallis corrected for Dunn's multiple comparisons, ## P < 0.01, ### P < 0.001 versus control, n ≥ 7 mice). C, control. [Color figure can be viewed at wileyonlinelibrary.com] reticulated platelets was fixed at 5% in control mice, according to Matic et al. [37] . Platelet total protein extracts were prepared and used to detect SAA protein by western blotting.
Super-resolution microscopy
Images of phalloidin-stained, CD62P-stained and SAAstained platelets were acquired on a Zeiss LSM 880 Confocal microscope (Zaventem, Belgium), in Airy Scan mode, with a 9 100 oil immersion objective (numerical aperture of 1.46) and an optical zoom of 9 5. Colocalization analyses were performed with the Coloc module in ZEN BLACK Software (Zeiss).
ELISAs and cytokine multiplex assays
Measurements of acute-phase proteins (APPs) and cytokines in plasma and colon were performed with ELISA or the Luminex assay (Bio Techne, Abingdon, UK), according to the manufacturer's instructions. 
Cell sorting of spleen myeloid cells and quantitative PCR analysis
Cell sorting of spleen Ly6G + and Ly6C + cells was performed on a FACSAria IIIu 4L SORP sorter (BD Biosciences). Total RNA was extracted from sorted cells with the miRNeasy mini kit (Qiagen, KJ Venlo, the Netherlands). Reverse transcription was performed with the Revert Aid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher, Asse, Belgium). Real-time PCR assays were performed with Syber PCR mix (Takara, Mountain View, CA) on a Light Cycler 480II (Roche, Vilvoorde, Belgium). The relative amount of mRNA was estimated by the comparative threshold cycle method, with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as a reference gene.
Generation of bone marrow-derived MDSCs
MDSCs were generated in vitro from tibia and femur bone marrow cells in the presence of granulocytemacrophage colony-stimulating factor according to Marigo et al. [39] . Cells were cultured for 4 days with or without platelet releasate. MDSCs were then isolated as above.
Isolation of LDN and NDN subsets
LDNs and NDNs were isolated from EDTA-anticoagulated whole blood samples by centrifugation over a Histopaque 1.077/1.119 double-density gradient 400 g for 30 min at room temperature (Sigma, Overijse, Belgium) (1.077 to collect LDNs, and 1.119 to collect NDNs).
Preparation of platelet releasates and proteomic analysis
Washed platelets were isolated from cancer and control mice (n = 5 mice per group), resuspended in Tyrode's buffer without bovine serum albumin, and activated with 1 U mL À1 thrombin for 5 min at 37°C under stirring (900 r.p.m.). Platelet-free supernatants were collected by two successive 5-min centrifugations at 1000 9 g before addition of protease and phosphatase inhibitors (Roche). The platelet releasates were frozen at À 80°C until being analyzed by two-dimensional ultraperformance liquid chromatography-liquid chromatography-tandem mass spectrometry. Raw proteomic data are available via ProteomeXchange with the identifier PXD006478.
Statistics
For proteomics data analysis, detailed statistical methods are provided in Supporting information in the Methods section. All other data are presented as mean AE standard error of the mean (SEM). As indicated in the legends of the figures, one-way ANOVA with Bonferroni or Tukey multiple comparison tests or Kruskal-Wallis tests were used to test comparisons among multiple groups, and two-tailed Student's t-tests or Mann-Whitney tests were used for comparisons between two groups. A P-value of < 0.05 was considered to be significant.
Results
Increased platelet activation and reactivity during carcinogenesis: inhibition by clopidogrel AOM/DSS causes dysplasia of colonic tissue as early as after 15 days, whereas the formation of adenocarcinoma and mucosa-infiltrating carcinoma occurred on days 65 and 80, respectively. We analyzed changes in platelet activation status during the course of carcinogenesis. The number of circulating activated platelets expressing active a IIb b 3 and exposing P-selectin on their surface, a marker of a-granule release, increased by approximately three-fold on day 80 (Fig. 1B) . Platelet reactivity to ex vivo stimulation by thrombin was enhanced at the stage of dysplasia, and returned to control values after 80 days (Fig. 1C) . Remarkably, thrombin-induced platelet a-granule release was augmented by 50-fold as compared with platelets from control mice. In contrast, platelets from cancer mice released less ATP than control platelets upon stimulation with thrombin (mean AE SEM: 0.13 AE 0.03 lM versus 0.86 AE 0.12 lM, P = 0.004). Clopidogrel fully inhibited the cancer-triggered augmentation of P-selectin-positive platelets observed on day 80 (Fig. 1B) , and it reduced by half thrombin-induced P-selectin exposure on platelets obtained on day 15 (Fig. 1C) . Thrombin-induced platelet agregation was also inhibited by clopidogrel (Fig. S1C) . Thus, at pretumoral stages, circulating platelets are more prone to releasing a-granule contents, whereas the number of activated and degranulated platelets increases when adenocarcinomas are formed.
Clopidogrel decreases colitis symptoms, dysplasia, and tumor multiplicity
We next assessed the effect of clopidogrel on inflammation and carcinogenesis. Clopidogrel reduced the tumor count by half on day 80 ( Fig. 2A) , and its effect persisted when tumors developed further, after 120 days (Fig. S2A ). Tumors were not smaller ( Fig. 2A) . It also reduced the DAI score recorded after 15 days (Fig. 2B) . At this time, we observed that clopidogrel limited diarrhea, without worsening bleeding ( Fig. 2B; Fig. S3 ). In agreement with the role of inflammation in tumor development, the DAI score on day 15 positively correlated with the number of tumors formed after 80 days (Fig. 2C ). Histological analysis revealed less dysplasia on day 15 (Fig. 2D) , and less adenocarcinoma and infiltrating carcinoma on day 80 (Fig. 2E) , in the colons of clopidogrel-treated mice. It is worth noting that the grade and proliferation rate (Ki67 staining) of 80-day tumors did not differ between the two groups ( Fig. S2B) . Together, these data suggest that clopidogrel prevents tumor initiation by dampening inflammation.
Clopidogrel inhibits myeloid cell-mediated immunosuppression
We then investigated whether clopidogrel affects cancer-elicited expansion of protumoral G-MDSCs (CD11b + Ly6C lo Ly6G + ) and M-MDSCs (CD11b + Ly6C hi Ly6G À ). As previously shown with the same mouse model [6] , these cells accumulate in blood at early stages of tumor development (Fig. 3A,B ). Although they cannot be distinguished from circulating neutrophils and monocytes on the basis of currently available cell surface markers, we found that the Ly6G + cells detected in blood of AOM/DSS mice were larger than cells from control mice (forward scatter value; Fig. 3D ). On day 65, we could separate distinct Ly6G + subpopulations by density gradient centrifugation. Similarly to what is seen in other mouse models of cancer, we showed that colitis-induced cancer was associated with the accumulation in blood of LDNs, which represented % 60% of Ly6G + cells (Fig. 3C ). As expected, these cells were not detected in the blood of control mice (not shown). Interestingly, clopidogrel fully prevented the increase in the number of Ly6G + cells that occurred after 15 days (Fig. 3B) . Furthermore, the size of Ly6G + cells from clopidogrel-treated mice was comparable to that of cells from control mice (Fig. 3D) , and the proportion of LDNs on day 65 dropped to % 30% (Fig. 3C) . These results indicate that clopidogrel treatment would inhibit cancer-induced accumulation of MDSCs. Both the other P2Y12 inhibitor, ticagrelor, and platelet depletion similarly prevented the early increase in the number of myeloid cells in blood (Fig. S4B) , indicating that the observed clopidogrel effects probably result from its antiplatelet action. To assess whether these myeloid cells showed altered immunosuppressive activity, we performed an allogenic mixed lymphocyte reaction assay, in which splenic G-MDSCs and M-MDSCs from tumor-bearing mice were cocultured with splenocytes from control mice. Whereas MDSCs isolated from non-treated mice significantly inhibited T-cell proliferation, cells from clopidogrel-treated mice could no longer exert their suppressive activity (Fig. 4A) . We further showed that clopidogrel modified the mRNA expression pattern of genes that are involved in MDSC immunosuppressive activities [38, 39] , with a significant reduction of Tgfb and Cebpb gene expression in GMDSCs (Fig. 4B ) and M-MDSCs (Fig. 4C ) being seen.
To corroborate these data with effects on tumors, we analyzed colon tissue infiltration by myeloid cells (CD11b In agreement with more efficient antitumor immunity in clopidogrel-treated mice, colons of the mice showed higher numbers of CD8 + T cells (Fig. 5C) . The absolute number of T-regulatory cells (CD4   +   CD25 + FoxP3 + cells) was also reduced in blood of clopidogrel-treated mice after 15 days and 65 days, possibly being related to weaker myeloid cell suppressive function (Fig. 5D) .
Platelets promote myeloid cell polarization towards a suppressive phenotype
In order to determine whether platelets can directly affect the immunosuppressive activity of myeloid cells, splenic G-MDSCs or M-MDSCs were cocultured with splenocytes in the presence or in the absence of platelets isolated from tumor-bearing mice or control mice. These experiments indicated that platelets enhanced MDSC-mediated inhibition of T-cell proliferation, and counteracted the clopidogrel effect (Fig. 6A) . Potentiation of immunosuppression was higher upon incubation with platelets from cancer mice. The immunosuppressive activity of in vitrogenerated MDSCs could also be induced when bone marrow cells were differentiated in the presence of releasates of platelets isolated at an early stage of cancer development (Fig. 6B) . Arginase-1 and C/EBPb mRNA expression levels were increased by coincubating GMDSCs with platelets from tumor-bearing mice (Fig. 6C,  D) . When G-MDSCs from clopidogrel-treated mice were used, platelets led to more significant induction of these two genes, and of Tgfb (Fig. 6C-E) . Arginase-1 expression was also induced in M-MDSCs cultured in the presence of platelets (Fig. 6C) . In vivo, cancer development was associated with the formation of G-MDSC-platelet aggregates in blood (Fig. 6F) , and platelet-neutrophil and platelet-monocyte aggregates were detected in the tumor microvasculature (Fig. 6G) . However, the levels of these aggregates were not reduced by clopidogrel. These data thus demonstrate a direct effect of platelets and platelet-derived soluble factors on myeloid cell suppressive function, occurring at the transcriptional level. 
Platelet releasates are enriched in APPs at an early stage of carcinogenesis
To obtain insights into the mechanisms by which plateletderived soluble factors regulate MDSC differentiation, we performed a proteomic analysis of releasates of platelets isolated at an early stage of tumor development (day 15) and from control mice. Three hundred and ninety-five proteins were identified (Table S1 ). Among them, 17 proteins were upregulated and 18 proteins were downregulated in cancer mice as compared with control mice (Table 1) . Interestingly, most proteins that were upregulated in the cancer group belong to the class of APPs, including SAA1, SAA2, serum amyloid P, haptoglobin, serine protease inhibitor A3N, a 1 -acid glycoproteins 1 and 2, inter-a-trypsin inhibitor, heavy chain (HC) 4, H3, and C-reactive protein (CRP). Remarkably, SAA1 expression showed a dramatic 125-fold increase in platelet releasates from cancer mice. Downregulated proteins included immunoglobulin chains, transthyretin, retinol-binding protein 4, kallikrein, adiponectin, paraoxonase 1, transaldolase, and septin 9, among others.
Platelets are major sources of APPs at an early stage of carcinogenesis
We then assessed changes in plasma levels of APPs during cancer development. Levels of SAA proteins, haptoglobin and, to a lesser extent, CRP showed transient increases, with peak values being observed before adenoma formation (Fig. 7A ). Clopidogrel treatment reduced the peak levels of plasma SAA proteins and haptoglobin, demonstrating a role for platelets in the release of these proteins at the pretumoral stage. By using confocal microscopy and western blotting, we further demonstrated that SAA proteins were upregulated in platelets from cancer mice as compared with those from control mice (Fig. 7B,E) . SAA proteins did not colocalize with Pselectin (overlap coefficient = 0.5 AE 013%, Pearson correlation coefficient = À 0.16 AE 0.26, means AE SEM, 11 images) (Fig. 7C) , indicative of distinct subcellular localization. Tumor development was accompanied by thrombocytosis (Fig. 7D) . Although the proportion of young reticulated platelets (Thiazole orange-bright) rapidly increased at the pretumoral stage (Fig. 7D) , these platelets expressed lower levels of SAA proteins than mature platelets (Fig. 7E) , suggesting that SAA proteins could be incorporated in circulating platelets rather than in megakaryocytes. Finally, in contrast to the effect on APPs, clopidogrel treatment did not affect plasma levels of IL-6, IL-10, or granulocyte colony-stimulating factor (G-CSF) (Fig. S5B ).
Discussion
We identified new platelet-dependent mechanisms by which inflammation contributes to CRC. We found that cancer development is associated with at least two early changes in platelet phenotype: (i) circulating platelets are hyper-reactive to thrombin; and (ii) platelet releasate is enriched in APPs. At early stages of carcinogenesis, platelets constitute a major source of the acute-phase SAA proteins. Indeed, inhibition of the cancer-elicited platelet release reaction by the antiplatelet drug clopidogrel strongly reduced plasma SAA protein levels. Clopidogrel inhibited the recruitment and/or expansion of immunosuppressive MDSCs and their infiltration into colonic mucosa at stages preceding dysplasia formation, which resulted in inhibition of tumor initiation. In addition, we found that platelets from cancer mice facilitated the differentiation of myeloid cells into immunosuppressive cells through increased mRNA expression of critical regulators of their activity, namely arginase-1 [40, 41] , TGF-b [42] , and C/EBPb [38, 43] . Our data thus indicate that carcinogenesis-associated myeloid suppressor cell expansion and phenotypic modification depend on platelets. At the pretumoral stage, platelet-derived systemic signals would play an important role. The large amounts of systemic SAA proteins could account for the shift in circulating neutrophil phenotype. Indeed, it has been reported that SAA protein injection enhances Ly6G + CD11b + cell expansion in mice [44] . Importantly, the same study showed that, upon incubation with SAA proteins, CD15 + CD11b + cells from healthy donors acquired the ability to inhibit T-cell proliferation, suggesting that our findings may not be restricted to mouse species. In addition to SAA proteins, we found that circulating levels of haptoglobin, another APP that is overexpressed in platelet releasates from cancer mice, reached levels equal to 1 mg mL
À1
, and remained elevated when tumor developed. It is noteworthy that, in addition to its antioxidant properties, haptoglobin can regulate the host immune response [45] , with anti-inflammatory and proinflammatory effects, depending on pathological context [46, 47] . Understanding the contribution of haptoglobin, and other identified APPs, to CAC will require further investigation.
The acute-phase response (APR) is the earliest stage of the innate immune responses to injury or infection, and results in the production of APPs by the liver. SAA proteins are the major APPs in mice [48] , whereas CRP predominates in humans. Proinflammatory cytokines, including IL-6, IL-1b, and TGF-b, produced early in [48] , our study is the first to demonstrate that platelets can be a major source of these APPs. Indeed, platelet inhibition potently inhibited early systemic elevation of the levels of these proteins, whereas it did not impact on IL-6 levels. Plasma G-CSF has previously been shown to be involved in carcinogenesis through neutrophil expansion and their conversion into protumorigenic immunosuppressive neutrophils [49, 50] . However, we showed that clopidogrel did not affect G-CSF levels (Fig. S5B) . Levels of the suppressive anti-inflammatory cytokine IL-10 [45] (Fig. S5B ) and its gene expression in MDSCs (Fig. 4C,D) were not modified by clopidogrel either, indicating that platelets may control neutrophil expansion via SAA proteins, independently of G-CSF and IL-10.
Interestingly, clinical studies have described an association between elevated APP levels and the risk of CRC, supporting a role for inflammation in colorectal carcinogenesis. In a large prospective study [51] , a 1.5-fold increased risk of colon cancer was observed among women with elevated levels of both CRP and SAA proteins. However, whether platelets contribute to APP levels in CRC patients remains to be determined. Also, it would be interesting to study whether antiplatelet drugs may reduce APP levels in patients, in relation to CRC risk. To date, there is no study on the impact of clopidogrel on CRC risk. It is noteworthy that a large population-based cohort of colorectal, breast and prostate cancer patients indicated that clopidogrel could be used safely in these patients [52] . Our study could therefore be the basis for the initiation of clinical trials aimed at improving CRC prevention by the use of antiplatelet agents.
Several studies have described anti-inflammatory effects of clopidogrel [53] . However, the mechanisms of such effects are not understood. Although the predominant mechanism of the effect of clopidogrel is thought to be a reduction in platelet P2Y12-dependent platelet-leukocyte interactions, we present evidence that clopidogrel could also act through inhibition of inflammatory marker release by platelets. Notably, we did not find any effect of clopidogrel on the levels of platelet-leukocyte aggregates in our mouse model. Finally, it is unlikely that Fig. 6 . Platelets (PLTs) promote the immunosuppressive differentiation and function of myeloid cells. (A) T-cell suppression assay performed as in Fig. 4 with or without PLTs isolated from azoxymethane (AOM)/dextran sodium sulfate (DSS) tumor-bearing mice. Data represent mean AE standard error of the mean (SEM), *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA clopidogrel may have off-target effects on inflammation that are not mediated by platelet P2Y12 receptor. We did indeed demonstrate in vitro the ability of platelets and platelet releasates to foster MDSC function and differentiation. In addition, we did not detect P2Y12 mRNA expression in MDSCs or in colon tumor cells (Fig. S4C ). Previous experimental studies described anticancer properties of clopidogrel. However, an effect on myeloid cellmediated immunosuppression has not yet been reported. For instance, in ectopic and orthotopic models of pancreatic tumors, clopidogrel restored hemostasis, decreased the size of tumors, and inhibited metastasis [54] . In a model of CD40-deficient BALB/NeuT mice, this drug reduced tumor growth [55] . Finally, in hepatoma, clopidogrel acted by attenuating platelet-tumor cell interactions [56] .
In line with our study, Rachidi et al. [53] recently showed that platelets constrain T-cell immunity against cancer through a GARP-TGF-b axis. In this study, releasates of platelets from wild-type mice suppressed the ability of T cells to inihibit B16-F10 melanoma growth, a processs shown to be driven by TGF-b. We could not observe consistent effects of platelet inhibition on colon TGF-b levels during the course of carcinogenesis (Fig. S5) . On the basis of previous studies demonstrating a role for myeloid cell TGF-b signaling in mouse CAC [54] , we cannot, however, exclude a direct or indirect contribution of platelets to this process. Evidence for an indirect effect is provided by our data indicating reduced Tgfb expression in MDSCs from clopidogrel-treated mice. In view of the complexity of TGF-b signaling, eliciting either protumoral or antitumoral effects depending on disease setting and cellular context [57] , further investigations are required to assess whether platelets play a direct role in CAC via TGF-b.
We describe a new mechanism by which platelets foster immunosuppression. We provide experimental evidence that platelets actively participate in inflammation-induced tumor initiation by promoting myeloid suppressor cell function. Importantly, our study suggests that antiplatelet regimens may represent a new paradigm for rational prevention of cancer in chronic inflammatory settings. P2Y12 inhibitors, through their ability to inhibit immunosuppressive myeloid cell expansion at the pretumoral inflammatory stage, may allow more efficient immune eradication of tumors. In addition, our study suggests that platelet SAA proteins may represent accurate biomarkers for early detection of patients at risk of developing cancer. Table S1 . List of proteins identified in mouse platelet releasates. Fig. 7 . Increased expression of serum amyloid A (SAA) proteins in plasma and platelets (PLTs) from mice with early-stage cancer. (A) Levels of SAA proteins, C-reactive protein (CRP) and haptoglobin were measured in plasma from azoxymethane (AOM)/dextran sodium sulfate (DSS) mice on days 15, 65, and 80. Levels were compared to those in control mice (C). The effect of clopidogrel treatment on peak levels of these proteins (day 15) is shown (right panel). Data represent mean AE standard error of the mean (SEM), *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA plus Tukey post hoc test for multiple comparisons (n ≥ 5 mice). (B) Super-resolution confocal microscopy images (9 1500) of mouse washed PLTs from AOM/DSS or control mice (day 15). The first panel shows a phalloidin staining (green) of the immobilized PLTs, the second shows CD62P staining (blue), the third shows SAA staining (red), and the fourth is a merged image. Scale bars: 2 lm. (C) Three-dimensional reconstruction of merged Z-stack images (9 1500), depicting phalloidin, CD62P and SAA staining (left), and CD62P and SAA staining (right). (D) Evolution of PLT count during AOM/DSS treatment (left). Numbers of reticulated PLTs (retPLTs) in earlystage AOM/DSS mice (day 15) treated or not treated with clopidogrel as compared with control mice (middle). Data represent mean AE SEM, Kruskal-Wallis test plus Dunn's test for multiple comparisons, *P < 0.05, n ≥ 6. (E) Western blotting detection of SAA in protein extracts of total PLTs, sorted retPLTs, and non-reticulated PTLs from AOM/DSS mice (+), as compared with to control mice (À). Liver extracts are shown as a positive control for SAA expression. Normalization was performed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
[Color figure can be viewed at wileyonlinelibrary.com] Fig. S1 . Ex vivo control of clopidogrel efficacy by light transmission aggregometry and flow cytometry. Fig. S2 . Clopidogrel decreases colitis severity and tumor multiplicity. Fig. S3 . Effect of clopidogrel therapy on the evolution of colitis severity index (DAI score) during carcinogenesis. Fig. S4 . Platelet depletion during AOM/DSS treatment inhibits MDSC recruitment similarly to treatment with ticagrelor or clopidogrel. No evidence for P2Y12 receptor expression in MDSCs or colon cancer cells. Fig. S5 . Colon TGF-b levels during carcinogenesis.
